T1	Disorder 10 31	Peripheral neuropathy
N1 	Reference T1 UMLS:C0031117	Peripheral neuropathy
T2	Pharmacological_substance 48 60	capecitabine
N1000 	Reference T2 MeSH:D000069287	capecitabine
T3	Pharmacological_substance 63 77	5-fluorouracil
N1001 	Reference T3 MeSH:D005472	5-fluorouracil
T4	Pharmacological_substance 79 83	5-FU
N1002 	Reference T4 MeSH:D005472	5-FU
N1003 	Reference T4 MeSH:D005472	5-FU
T5	Disorder 96 117	peripheral neuropathy
N2 	Reference T5 UMLS:C0031117	peripheral neuropathy
T6	Pharmacological_substance 140 152	Capecitabine
N1004 	Reference T6 MeSH:D000069287	Capecitabine
T7	Pharmacological_substance 154 157	CAP
N1005 	Reference T7 MeSH:D000069287	CAP
T8	Pharmacological_substance 176 180	5-FU
N1006 	Reference T8 MeSH:D005472	5-FU
N1007 	Reference T8 MeSH:D005472	5-FU
T9	Disorder 185 206	peripheral neuropathy
N3 	Reference T9 UMLS:C0031117	peripheral neuropathy
T10	Pharmacological_substance 223 226	CAP
N1008 	Reference T10 MeSH:D000069287	CAP
T12	Pharmacological_substance 291 294	CAP
N1009 	Reference T12 MeSH:D000069287	CAP
T13	Disorder 332 349	pancreatic cancer
N4 	Reference T13 UMLS:C0346647	pancreatic cancer
T15	Disorder 440 461	peripheral neuropathy
N5 	Reference T15 UMLS:C0031117	peripheral neuropathy
T16	Pharmacological_substance 481 484	CAP
N1010 	Reference T16 MeSH:D000069287	CAP
T19	Pharmacological_substance 606 609	CAP
N1011 	Reference T19 MeSH:D000069287	CAP
T21	Pharmacological_substance 742 745	CAP
N1012 	Reference T21 MeSH:D000069287	CAP
T24	Pharmacological_substance 931 934	CAP
N1013 	Reference T24 MeSH:D000069287	CAP
T28	Disorder 1283 1317	sensorimotor peripheral neuropathy
T30	Disorder 1424 1443	Neurologic symptoms
N6 	Reference T30 UMLS:C0235031	Neurologic symptoms
T31	Pharmacological_substance 1468 1471	CAP
N1014 	Reference T31 MeSH:D000069287	CAP
T32	Pharmacological_substance 1536 1539	CAP
N1015 	Reference T32 MeSH:D000069287	CAP
T36	Disorder 1682 1703	peripheral neuropathy
N7 	Reference T36 UMLS:C0031117	peripheral neuropathy
T37	Pharmacological_substance 1709 1713	5-FU
N1016 	Reference T37 MeSH:D005472	5-FU
N1017 	Reference T37 MeSH:D005472	5-FU
T38	Disorder 1723 1736	Neurotoxicity
N8 	Reference T38 UMLS:C0235032	Neurotoxicity
T39	Disorder 1849 1862	neurotoxicity
N9 	Reference T39 UMLS:C0235032	neurotoxicity
T40	Pharmacological_substance 1912 1915	CAP
N1018 	Reference T40 MeSH:D000069287	CAP
T42	Pharmacological_substance 1942 1946	5-FU
N1019 	Reference T42 MeSH:D005472	5-FU
N1020 	Reference T42 MeSH:D005472	5-FU
T43	Pharmacological_substance 2005 2009	5-FU
N1021 	Reference T43 MeSH:D005472	5-FU
N1022 	Reference T43 MeSH:D005472	5-FU
T44	Pharmacological_substance 2037 2056	fluoro-beta-alanine
T45	Pharmacological_substance 2134 2137	CAP
N1023 	Reference T45 MeSH:D000069287	CAP
T46	Disorder 2206 2219	neurotoxicity
N10 	Reference T46 UMLS:C0235032	neurotoxicity
T11	Subject 269 280	28 patients
T41	Speculation_cue 231 248	not been reported
T47	Subject 382 394	two patients
T50	Disorder 772 790	right leg weakness
N11 	Reference T50 UMLS:C2218016	right leg weakness
T52	Disorder 862 903	perioral and upper extremity paresthesias
T55	Subject 1321 1334	both patients
T56	Subject 753 762	Patient A
T57	Subject 842 851	Patient B
T60	Subject 1363 1376	both patients
T64	Pharmacological_substance 1783 1787	5-FU
N1024 	Reference T64 MeSH:D005472	5-FU
N1025 	Reference T64 MeSH:D005472	5-FU
T67	Pharmacological_substance 2013 2035	its active metabolites
T69	Speculation_cue 2105 2114	potential
T70	Manner_cue 1717 1721	rare
T20	Manner_cue 124 132	uncommon
T14	Subject 1866 1882	our two patients
T25	Pharmacological_substance 820 827	CAP-XRT
T23	Speculation_cue 1993 1999	likely
